Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.

Go here to see the original:
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place March 20-22, 2025 in Washington, D.C.

View post:
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

TAMPA, Fla., March 21, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, is pleased to announce that the Company’s shareholders approved the following proposals (the “Proposals”) at the Company’s special meeting held today, March 21, 2025 (the “Meeting”):

Visit link:
Better Choice Company Shareholders Overwhelmingly Approve Acquisition of SRx Health Solutions and Related Proposals

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.

Read the original here:
Impact Biomedical Inc. Announcement Stock Activity/Pricing

ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the period from February 3, 2025 to March 18, 2025, the Company has not met the minimum bid price requirement set forth in Listing Rule 5450(a)(1) during that period. The Notice is only a notification of deficiency and has no immediate effect on the listing of the Company’s American Depositary Shares (“ADS”). The Company’s ADSs will continue to trade on the Nasdaq Global Market at this time. The Company’s receipt of the Notice does not impact the Company’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

Read the original post:
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction

Go here to read the rest:
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting...

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results.

See the rest here:
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

No Shareholder Action is Required at this Time No Shareholder Action is Required at this Time

See the article here:
Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Company Announcement

Read the original:
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

AURORA, Colo., March 22, 2025 (GLOBE NEWSWIRE) -- Arialief is a unique nerve pain and discomfort relief supplement with natural herbs and powerful ingredients. The unique composition of the formula makes it stand out among the competitors, which usually goes for the surface.

See more here:
Arialief Reviews (Is It Safe And Legit To Use?) What Do Arialief Consumer Reports Say About Its Efficacy?

Skin cells can now be directly converted into neurons  Earth.com

Read the original here:
Skin cells can now be directly converted into neurons - Earth.com

Dame Sandra Biskind And Stem Cell Rejuvenation  Anti Aging News

Follow this link:
Dame Sandra Biskind And Stem Cell Rejuvenation - Anti Aging News

Keio University team says stem cell treatment helped improve spine injuries  The Japan Times

View post:
Keio University team says stem cell treatment helped improve spine injuries - The Japan Times

Japan team says stem cell treatment helped improve spinal cord injuries | NHK WORLD-JAPAN News  NHK WORLD

Read more:
Japan team says stem cell treatment helped improve spinal cord injuries | NHK WORLD-JAPAN News - NHK WORLD

PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the “Dividend”) to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be April 11, 2025 (the “New Record Date”). Subject to the Board’s right to further change the New Record Date, the payment date (the “Payment Date”) will be determined by subsequent resolutions of the Board, which will be within 60 days following the New Record Date.

Read more here:
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of...

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034.

See original here:
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has signed a distribution agreement with Duchefa Farma B.V. (“Duchefa”) of Haarlem, Netherlands, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market.

Continue reading here:
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands

Please read the announcement in PDF

See the rest here:
Transactions under Novonesis’ share buyback program

Company Announcement

See the original post here:
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

MESQUITE, NV, March 10, 2025 (GLOBE NEWSWIRE) -- March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the rapidly growing meme coin market. Inspired by the meteoric success of recent meme coins launched by high-profile figures like Donald Trump and Melania Trump, $CBDS is forming a new subsidiary, MEME COINS Inc., to drive acquisitions and investments in the space while protecting shareholder equity.Riding the Wave of Cultural RelevanceMeme coins have become a powerful cultural and financial force, with billions of dollars traded daily. Their unique blend of viral marketing, community-driven support, and speculative appeal has attracted both retail and institutional investors. The success of high-profile meme coins underscores the immense potential for innovation in this space.“As we’ve seen with recent launches, meme coins have evolved into a mainstream asset class, engaging investors in ways traditional cryptocurrencies have not. Through the formation of MEME COINS Inc. we are structuring our expansion to maximize opportunities while minimizing dilution for CBDS shareholders,” said David Tobias, CEO of Dogecoin Cash, Inc.Why the Meme Coin Market?The exponential growth of the meme coin market is driven by:Global Appeal – Meme coins transcend borders and demographics, fueled by internet culture. Community Power – Strong online communities drive engagement and long-term value. New Revenue Streams– Meme coins can integrate into broader ecosystems, creating opportunities for DeFi, NFTs, and gaming. Cultural Influence – Endorsements from public figures and brands amplify adoption and legitimacy. CBDS and MEME COINS Inc. will build a diversified portfolio of meme coin assets and projects that combine cultural relevance with sound financial utility.Formation of MEME COINS Inc. and Strategic Acquisition PlanTo execute this vision while avoiding dilution to $CBDS shareholders, the company is launching a wholly owned subsidiary, MEME COINS Inc., which will focus on:Acquiring Established Meme Coins – Targeting assets like Dogecoin and other high-potential meme coins. Issuing Preferred Shares – MEME COINS Inc. will raise funds through preferred shares rather than issuing common stock, ensuring that CBDS shareholders maintain their equity positions. Strategic Partnerships & Investments – Investing in new and existing meme coin projects with strong community engagement and financial potential. This approach allows $CBDS to capitalize on the meme coin boom while preserving its equity structure and protecting long-term investor value.The $CBDS Business PlanDogecoin Cash, Inc. and MEME COINS Inc. will execute a three-pronged strategy:1. Development of Proprietary Meme Coins – Launching branded meme coins with real-world applications, such as charity contributions, gamification, and exclusive content access. 2. Partnerships with Influencers – Collaborating with cultural icons and internet influencers to drive viral marketing campaigns. 3. Community-First Ecosystem – Creating a platform where meme coin communities can trade, engage, and participate in decentralized governance. Commitment to Sustainable GrowthDogecoin Cash, Inc. is uniquely positioned to add legitimacy and long-term value to the meme coin market by emphasizing transparency, security, and scalability. Through responsible development, strategic acquisitions, and financial innovation, the company aims to redefine how meme coins are perceived and utilized.Looking AheadDogecoin Cash, Inc. invites investors, developers, and the broader cryptocurrency community to join us in this bold venture. Through MEME COINS Inc., we are not only embracing the future of digital finance but also ensuring that our investors benefit from this explosive market with minimal dilution.For more information about Dogecoin Cash, Inc. and MEME COINS Inc. visit www.cbds.com.

Link:
Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc.